MDxHealth Provides Third Quarter 2010 Business Update
(Thomson Reuters ONE) -
DURHAM, NC, and LIEGE, BELGIUM - November 4, 2010 - MDxHealth SA (NYSE Euronext
Brussels & Amsterdam: MDXH), a leading molecular diagnostics company focused on
personalized medicine in the field of cancer, today issued its business update
for the quarter ended September 30, 2010.
Q3 2010 Highlights
* Significantly improved key financial performance indicators
* Total revenue increased by 4%
* Commercial revenue increased by 74%
* EBIT improved by 31%
* Net result improves by 30%
* Net Cash flows improve by 30%
* Signed agreement with GlaxoSmithKline Biologicals (GSK) for companion
diagnostic tests for GSK's immunotherapeutic oncology program
* Out-licensed biomarkers to Exact Sciences for its colorectal cancer
screening program
* Strengthened management team with key hires
* Implemented new strategy, name change & corporate re-branding
* Aligned company structure and activities to match needs of new strategy,
including restructuring of sites and personnel
MDxHealth expanded its relationship with GlaxoSmithKline Biologicals SA to
pursue the development and testing of new companion diagnostic tests that can
potentially be used with GSK's immunotherapeutic oncology program. This
agreement reinforces MDxHealth's focus on the growing and important field of
pharmacodiagnostics, in which pharmaceutical companies and treating physicians
increasingly rely on molecular biomarkers to tailor therapeutics. The aim is to
deliver the right treatment to patient based on his or her individual genetic
makeup. During the quarter, MDxHealth also out-licensed certain biomarkers to
Exact Sciences for use in their test for colorectal cancer screening. Exact
Sciences has initiated clinical trials for this test and has stated that it
intends to file for FDA clearance in 2012.
MDxHealth has completed the main organizational changes to implement its new
strategy. Among other things, this involved centralizing all European lab
activities in Belgium, and hiring several experienced executives. MDxHealth now
has a strong team of some 40 employees fully dedicated to give shape to the
company's new mission and vision. To highlight its new focus on personalized
medicine and on direct sales to doctors and pharmaceutical and biotechnology
companies, the company changed its name from OncoMethylome Sciences to
MDxHealth.
"In short order we have moved into an exciting and new era for the company. Our
DNA methylation technology platform is ideally suited to rapidly develop
products for personalized cancer care, and direct commercialization to
clinicians, leveraging CLIA labs for distribution. The Board, management and
employees are extremely motivated and focused to roll out our new strategy, and
I am confident that we can deliver on the company's tremendous potential," said
Dr. Jan Groen, Chief Executive Officer of MDxHealth.
Key non-audited financials, as of 30.09.2010
Amounts as at and for the three months ended
+------------------------------+----------------+---------------+
| Euro thousands | Sept. 30, 2010 | Sept 30, 2009 |
+------------------------------+----------------+---------------+
| Revenues | 669 | 577 |
+------------------------------+----------------+---------------+
| EBITDA Income (Loss) | (1,405) | (2,797) |
+------------------------------+----------------+---------------+
| EBIT Operating Income (Loss) | (1,469) | (3,036) |
+------------------------------+----------------+---------------+
| Net Profit (Loss) | (1,490) | (2,907) |
+------------------------------+----------------+---------------+
| Cash and cash equivalents | 11,356 | 21,065 |
+------------------------------+----------------+---------------+
Amounts as at and for the nine months ended
+------------------------------+----------------+---------------+
| Euro thousands | Sept. 30, 2010 | Sept 30, 2009 |
+------------------------------+----------------+---------------+
| Revenues | 1,927 | 1,845 |
+------------------------------+----------------+---------------+
| EBITDA Income (Loss) | (6,469) | (8,862) |
+------------------------------+----------------+---------------+
| EBIT Operating Income (Loss) | (6,641) | (9,565) |
+------------------------------+----------------+---------------+
| Net Profit (Loss) | (6,486) | (9,247) |
+------------------------------+----------------+---------------+
| Cash and cash equivalents | 11,356 | 21,065 |
+------------------------------+----------------+---------------+
For the 9 months ended September 30, 2010,
* Total revenues grew by 4%, however the revenue mix has changed. Commercial
revenues grew by 74% (mainly due to an increased number of tests sold)
offset by a similar decrease in grant revenues.
* Net results improved by approx. 30% due primarily to a reduction of R&D and
other operating costs. In Q3 2010, the company completed the transfer of
all of its previously decentralized R&D activities to its ISO certified lab
in Belgium.
* One-time cash payments of approximately EUR 1 million were made for
restructuring of sites and personnel in 2010. Part of these costs were
recorded as provisions in Q4 2009.
Outlook for Q4 and FY 2010
In Q4 2010 we expect continued financial improvement from commercial revenue
increases and cost reductions. However, the full effect of the change in
strategy will not be seen until 2011. Excluding one-time restructuring charges,
the 2010 operating costs are expected to be approximately 25% lower compared to
2009. The full year 2010 revenues are expected to be similar to 2009. The
company has hired an advisor to examine potential commercial distribution
targets and is evaluating new fund raising opportunities to support the
company's growth ambitions.
About MDxHealth
MDxHealth(TM) is a leading molecular diagnostics company that develops and
commercializes oncology based molecular diagnostic testing for personalized
medicine. The company's tests are based on proprietary gene methylation
technology and assist physicians with the accurate diagnosis of cancer,
prognosis of recurrence risk, and prediction of response to a specific therapy.
MDxHealth collaborates with leading cancer research centers such as Johns
Hopkins University, Duke University, Lovelace Respiratory Research Institute,
Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering and
major European medical centers. The company has a number of commercial and
collaborative partnerships with LabCorp, Merck & Co./Schering-Plough,
GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen and other industry
leaders.
For more information:
Dr. Jan Groen, CEO Hans Herklots
MDxHealth Capricorn One
+32 4.364.20.70 +41 79 598 7149
IR(at)MDxHealth.com
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the Company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation.
[HUG#1458605]
2010-11-04 MDxHealth Provides Third Quarter 2010 Business Update ENG:
http://hugin.info/137314/R/1458605/398156.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MdxHealth via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 04.11.2010 - 07:51 Uhr
Sprache: Deutsch
News-ID 48404
Anzahl Zeichen: 9950
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 190 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MDxHealth Provides Third Quarter 2010 Business Update"
steht unter der journalistisch-redaktionellen Verantwortung von
MdxHealth (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
